Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy.

ABSTRACT:

Importance

The EVEREST II trial showed that for patients with polypoidal choroidal vasculopathy (PCV), intravitreal ranibizumab in combination with verteporfin photodynamic therapy improves visual acuity relative to ranibizumab monotherapy. However, whether combination therapy is incrementally cost-effective relative to monotherapy during a lifetime is unclear.

Objective

To assess the incremental cost-effectiveness of combination therapy compared with ranibizumab monotherapy in patients with PCV.

Design, setting, and participants

This model-based, economic evaluation used 2018 unit cost data from a tertiary eye hospital in Singapore, first- and second-year outcomes and resource use data from a multicenter trial across various Asian countries (EVEREST II) to model a hy

SUBMITTER: Doble B 

PROVIDER: S-EPMC6990685 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature